Skip to main content

Table 2 Pathological characters and treatments of patients with stage I OEC

From: Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma

  EOC
Total number 78
Tumor size(cm)  
 Median [IQR] 8 (6,12)
 Range 2.0–25.0
Side of ovarian tumor  
 Unilateral 63 (80.8%)
 Bilateral 15 (19.2%)
Ascitesb  
 Positive 8 (10.3%)
 Negative 70 (89.7%)
Grade  
 1 35 (44.9%)
 2 26 (33.3%)
 3 17 (21.8%)
Mixed histologyc  
 Yes 5 (6.4%)
 No 73 (93.6%)
EM associated  
 Yes 23 (29.5%)
 No 55 (70.5%)
Endometrial disordersf  
 Yes 21 (26.9%)
 No 57 (51.1%)
ER presentatione  
 Number 37
 Positive 25 (67.6%)
 Negative 12 (32.4%)
PR presentatione  
 Number 37
 Positive 29 (78.4%)
 Negative 8 (21.6%)
Residual disease  
 No or <1 cm 77 (98.7%)
  > 1 cm 1 (1.3%)
Lymphadenectomy  
 Yes 72 (97.4%)
 No 6 (2.6%)
Para-aortic lymphadenectomya  
 Number 72
 Yes 45 (62.5%)
 No 27 (37.5%)
Numbers of lymph nodes dissected  
 Number 72
 Median(IQR, number) 18 [11,27]
 Range (number) 2–48
Chemotherapy  
 Yes 70 (89.8%)
 No 5 (6.4%)
 Unclear 3 (3.8%)
Chemotherapy regimen  
 Number 70
  Platinum based 68 (97.1%)
  Others 2 (2.9%)
Platinum chemotherapy cycle  
 Number 68
  < 4 21 (30.9%)
  > =4 47 (69.1%)
Platinum-resistance  
 Number 68
 Yes 3 (4.3%)
 No 65 (95.7%)
  1. Abbreviation: EM endometriosis, ER estrogen receptor, PR progesterone receptor
  2. aincluding dissection of common iliac lymph node and para-aortic lymph node
  3. bfindings of malignant cells in ascites or peritoneal washing
  4. cincluding endometrioid carcinoma mixed with components of serous or clear cell subtypes
  5. dincluding 15 cases of endometrial carcinoma (19.2%), one of endometrial hyperplasia (1.3%), and 5 of endometrial polyps (6.4%)
  6. eaccording to the retrospectively reviewing the results of immunohistogical staining of ER and PR